

**The *in vitro* and *in vivo* Formation and Potency of 6 β -Naltrexol,
the Major Human Metabolite of Naltrexone**

Susan J Porter BSc (Hons)

**Discipline of Pharmacology,
School of Health Sciences
University of Adelaide**

May 2010

Table of Contents

Abstract	i
Acknowledgements.....	iv
List of abbreviations used in this thesis	v
1. Naltrexone and 6β-Naltrexol: A Review of the Literature.....	1
1.1. Summary	1
1.2. Opioid Pharmacology	1
1.2.1. History	1
1.2.2. Opioid Structure	3
1.2.3. Opioid Receptors.....	4
1.2.4. Receptor Tolerance and Dependence	12
1.3. Naltrexone and 6β-Naltrexol	14
1.3.1. Naltrexone History	14
1.3.2. Chemistry of Naltrexone and its Metabolites	14
1.4. Determination of Naltrexone and its Metabolites in Biological Fluids	16
1.4.1. Thin layer chromatography (TLC).....	17
1.4.2. Gas chromatography (GC).....	17
1.4.3. Mass spectrometry (LC-MS[MS], GC-MS[MS]).....	18
1.4.4. High Pressure Liquid Chromatography (HPLC)	20
1.4.5. Summary.....	21
1.5. Metabolism of Naltrexone.....	22
1.6. Pharmacokinetics of Naltrexone.....	26
1.7. Pre-Clinical Pharmacology of Naltrexone and its Metabolites	31
1.8. Clinical Pharmacology of Naltrexone.....	36
1.8.1. Toxicity of Naltrexone	36
1.8.2. Naltrexone Pharmacotherapies	37
1.8.3. Opioid Detoxification.....	39
1.8.4. Low Dose and Ultralow Dose Naltrexone Therapy	40
1.9. Summary	42
1.10. Aims of the Current Project	42
2. Synthesis of 6β-naltrexol from naltrexone.....	44
2.1. Introduction	44
2.2. Aim	45
2.3. Materials and Methods	46
2.3.1. Chemicals	46
2.3.2. Analytical equipment	46
2.3.3. Naltrexone hydrochloride reduction.....	47
2.3.4. Octanol:pH 7.4 Buffer Study	48
2.4. Results	49
2.4.1. Naltrexone HCl reduction.....	49
2.4.2. Octanol:Phosphate buffer partitioning	56
2.5. Discussion.....	57

3. High performance liquid chromatography (HPLC) quantification of naltrexone and 6β-naltrexol in biological fluids.....	59
3.1. Introduction	59
3.2. Specific aims of the current project.....	59
3.3. Chemicals	60
3.4. Quantification of 6β-naltrexol in human liver cytosolic incubations	60
3.4.1. Introduction.....	60
3.4.2. HPLC instrumentation and chromatography conditions	61
3.4.3. Cytosol assay method.....	61
3.4.4. Cytosol assay validation	62
3.4.5. Cytosol assay data analysis.....	62
3.4.6. Cytosol assay results and discussion	62
3.5. Quantification of naltrexone and 6β-naltrexol in plasma.....	66
3.5.1. Introduction.....	66
3.5.2. Plasma assay conditions	66
3.5.3. Plasma sample preparation	66
3.5.4. Plasma assay validation procedure.....	67
3.5.5. Calibration curve and validation analysis.....	68
3.5.6. Results and Discussion	68
3.6. Simultaneous quantification of naltrexone and 6β-naltrexol in urine	72
3.6.1. Urine assay conditions.....	72
3.6.2. Urine sample preparation.....	72
3.6.3. Urine assay validation	72
3.6.4. Urine assay results and discussion	73
3.7. Simultaneous assay for naltrexone and 6β-naltrexol in plasma ultrafiltrates ..	76
3.7.1. Introduction.....	76
3.7.2. Ultrafiltrate assay conditions	76
3.7.3. Ultrafiltrate sample preparation	76
3.7.4. Ultrafiltrate assay validation.....	77
3.7.5. Ultrafiltrate assay results and discussion.....	77
3.8. Simultaneous assay for naltrexone and 6β-naltrexol in saliva	77
3.8.1. Introduction.....	77
3.8.2. Saliva assay conditions.....	77
3.8.3. Saliva sample preparation.....	78
3.8.4. Saliva assay validation	78
3.8.5. Saliva assay Results and Discussion	79
3.9. Naltrexone and 6β-naltrexol analyses in whole blood	81
3.9.1. Introduction.....	81
3.9.2. Whole blood assay conditions	81
3.9.3. Whole blood sample preparation	81
3.9.4. Whole blood assay validation	82
3.9.5. Whole blood results and discussion	82
3.10. Discussion of naltrexone and 6β-naltrexol quantification in biological fluids ..	82
4. Kinetics and Inhibition of the Formation of 6β-Naltrexol from Naltrexone in Human Liver Cytosol	84
4.1. Introduction	84
4.2. Aims.....	85

4.3. Methods	86
4.3.1. Introduction.....	86
4.3.2. Chemicals	86
4.3.3. Preparation of cytosol and microsomes.....	86
4.3.4. Measurement of cytosolic and microsomal protein concentrations.....	87
4.3.5. HPLC Conditions	87
4.3.6. 6 β -naltrexol quantification	87
4.3.7. Time-dependency studies	88
4.3.8. Protein-dependency studies	88
4.3.9. Cytosolic incubations	88
4.3.10. Microsomal incubations	89
4.3.11. Inhibition studies with chemical inhibitors	89
4.3.12. Problems encountered with cytosolic incubations and inhibitor studies.....	90
4.3.13. Data analyses	91
4.4. Results	92
4.4.1. Validation and on-going performance of the assay.....	92
4.4.2. Time-dependency studies	94
4.4.3. Protein-dependency studies	94
4.4.4. Solutions to problems encountered in cytosol incubations	96
4.4.5. Kinetics of 6 β -naltrexol formation from naltrexone	96
4.4.6. Inhibition with chemical inhibitors	98
4.5. Discussion	101
5. Pharmacokinetics of Naltrexone in Healthy Volunteers	105
5.1. Introduction	105
5.2. Aim	107
5.3. Methods	107
5.3.1. Drugs	107
5.3.2. Volunteers.....	107
5.3.3. Experimental Design and Protocol.....	108
5.3.4. Analyses of biofluids and calculations.....	110
5.3.5. Pharmacokinetic and Statistical Analyses	111
5.4. Results	112
5.4.1. Patient demographics	112
5.4.2. Ongoing performance of the assays	114
5.4.3. Pharmacokinetics of Intravenous Naltrexone Administration.....	117
5.4.4. Pharmacokinetics of Oral Naltrexone Administration	119
5.4.5. Plasma protein binding	129
5.4.6. Blood:Plasma Concentration Ratio	129
5.4.7. Side-Effects and Mood Evaluation	129
5.5. Discussion	130
6. <i>In vivo</i> and <i>in vitro</i> potency studies of 6β-naltrexol.	135
6.1. Introduction	135
6.2. Aim	136
6.3. Materials and Methods	136
6.3.1. Chemicals	136
6.3.2. <i>In vitro</i> potency study.....	137
6.3.3. <i>In vivo</i> potency study.....	137
6.3.4. Data Analysis.....	138

6.4. Results	139
6.4.1. <i>In vitro</i> potency studies	139
6.4.2. <i>In vivo</i> potency studies	142
6.5. Discussion	144
7. Overall Discussion	148
7.1. Synthesis of 6 β -naltrexol from naltrexone	148
7.2. The <i>in vitro</i> metabolism of naltrexone	148
7.3. Quantification of naltrexone and 6 β -naltrexol in fluids	148
7.4. Human Pharmacokinetic studies.....	149
7.5. <i>In vitro</i> and <i>in vivo</i> potency studies.....	151
7.6. Conclusions	152
Appendix 1: Publications in Support of this Thesis	155
Bibliography	170

Abstract

6 β -Naltrexol is the major human metabolite of naltrexone, which is an opioid receptor antagonist used in the treatment of opioid and alcohol dependence. This metabolite is thought to contribute to the pharmacological effects of naltrexone, particularly the longer duration of naltrexone compared to naloxone (the prototypical opioid receptor antagonist), but to what extent has not been fully described.

6 β -Naltrexol was synthesised from naltrexone in order to conduct the studies contained in this thesis as it was not commercially available at the time. Additionally, a validated HPLC assay method needed to be developed to quantify naltrexone and 6 β -naltrexol for the *in vivo* and *in vitro* studies contained within. 6 β -Naltrexol was successfully synthesised, and the HPLC assay was developed for simultaneous analysis of the parent and metabolite in a number of biological fluids, and performed with a high degree of precision and accuracy throughout.

The enzyme kinetics for the formation of 6 β -naltrexol from naltrexone were determined *in vitro* in human liver cytosolic and microsomal preparations. Additionally, several compounds were tested for their likelihood of inhibition of this formation. The hepatic enzymatic formation of 6 β -naltrexol from naltrexone was confined to the cytosolic and not the microsomal fraction, exhibited considerable intersubject variability and could be inhibited by a number of compounds. The most potent of these were certain steroid hormones, and naloxone.

The *in vivo* pharmacokinetics and bioavailability of naltrexone, and the formation of 6 β -naltrexol, were also assessed after oral and intravenous administration of naltrexone to healthy volunteers. Naltrexone and 6 β -naltrexol were quantified in the plasma, urine and saliva of these subjects. Additionally, the correlation between 6 β -naltrexol concentrations and increased subjective side-effects reported previously was assessed. As with the *in vitro* studies, there was a high degree of interindividual variation of pharmacokinetic parameters. It was found that saliva is possibly a better alternative to plasma in assessing naltrexone status following the 50 mg dose used clinically. There was no correlation between high biofluid concentrations of 6 β -naltrexol and an increase in subjective side effects after intravenous or oral naltrexone administration.

Potency studies and assessment of the duration of antagonistic activity of 6 β -naltrexol were conducted *in vitro* in electrically-stimulated guinea pig ileum preparations (blocking the

Susan J Porter, PhD Thesis, 2010

morphine-induced twitch height) and *in vivo* in mice (reversing morphine-induced antinociception). The potencies were compared to the parent naltrexone, and naloxone. Naltrexone was more potent than naloxone in the guinea pig ileum preparation and interestingly, 6 β -naltrexol was found to be 4.5-fold more potent than naloxone, and nearly three times more potent than naltrexone in this preparation. The high potency found in the *in vitro* study was not reflected in the *in vivo* mouse study, in which 6 β -naltrexol showed only 1/185th the potency of naltrexone. Whereas the *in vivo* potency of 6 β -naltrexol was much lower than that of naltrexone or naloxone, the duration of action was much longer.

The *in vivo* potency of 6 β -naltrexol is lower than that of its parent compound naltrexone, but the longer duration of action, and the significantly higher plasma concentrations of this metabolite after an oral dose of naltrexone indicate that 6 β -naltrexol will contribute significantly to the therapeutic effects of naltrexone.

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Susan Porter and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Susan J Porter

Acknowledgements

I would like to thank my supervisors Professor Jason White, and particularly Professor Andrew Somogyi for continued advice, patience and understanding throughout my years in the Department and beyond.

Additionally, I would like to sincerely thank staff and students of the then Department of Clinical and Experimental Pharmacology, University of Adelaide, particularly Andrew Menelaou for his invaluable help with assays, and for always being there, Mark Hutchinson for all the help with my computing and life “dramatics” and David Foster for his help and guidance in all things pharmacokinetic. Thanks also to Gordon Crabb for his support in the computing department, and not forgetting my Adelaide Oval tickets. Many thanks also to A/Prof Rod Irvine for his continual advice and along with Gordon and Cath Danz, Friday night beers.

I acknowledge and thank Dr Marc Kimber and Dr David Ward, Chemistry Department, University of Adelaide, for their assistance and guidance during the synthesis of 6β -naltrexol. Additionally, I would like to thank Dr Sandor Hosztafi, ICN Alkaloida Co, Budapest, Hungary for his kind gift of 6β -naltrexol, and Professor Howard Morris for his gift of steroid compounds used to study inhibitors of the metabolism of naltrexone.

My thanks go also to the Royal Adelaide Hospital for providing a Dawes Postgraduate Scholarship, without which my studies would never have begun. Thanks also to staff at the Institute of Medical and Veterinary Science, specifically Howard Morris, Peter O’Loughlin, Kingsley Valledares, David Neilsen and Allan Rofe, for their continued financial support which enabled me to eat whilst doing this project.

On a more personal note I would like to acknowledge the huge amount of support and guidance from Howard Morris and Allan Rofe and their belief that I could do it. To all my friends who helped me along the way, thank you. Finally, thanks again for everything Marky.

List of abbreviations used in this thesis

The abbreviations and prefixes of the International System of units have been used in this thesis, except for the alternatives listed below. Additional abbreviations and terminology, and pharmacokinetic symbols are also listed.

AKR	aldo-keto reductase family of enzymes
ALT	alanine aminotransferase
AST	aspartate aminotransferase
AUC	area under the concentration-time curve
cAMP	cyclic 3',5'-adenosine monophosphate
CL	total systemic clearance
CL _{int}	intrinsic clearance
CL/F	apparent oral clearance
CL _R	apparent renal clearance
C _{max}	maximum measured concentration
CNS	central nervous system
COMT	catechol -O-methyltransferase
CV	coefficient of variation (expressed as a percentage)
CYP450	cytochrome P450 enzyme
DADLE	D-Ala-Δ-leu-enkephalin
DAMGO	[D-Ala ² ,N-MePhe ⁴ ,Gly-ol ⁵]enkephalin
DD	dihydrodiol dehydrogenase
DSLET	[D-Ser ² ,Leu ⁵ ,Thr ⁶]enkephalin
DRG	dorsal root ganglion
DSM-IV	Diagnostic and Statistical Manual (Volume IV)
ECD	electrochemical detection
EC ₅₀	effective concentration eliciting 50% of maximal effect
ED ₅₀	effective dose eliciting 50% of maximal effect
fu	fraction unbound in plasma
GC	gas chromatography
GPCR	guanine nucleotide binding (G) -protein coupled receptor
HEK	human embryonic kidney
HMN	2-hydroxy-3-methoxynaltrexone
HPLC	high pressure (performance) liquid chromatography
HQC	high quality control
IC ₅₀	concentration of antagonist that inhibits agonist action by 50%
ID ₅₀	dose of antagonist that inhibits agonist action by 50%
icv	intracerebroventricular
im	intramuscular
ip	intraperitoneal
it	intrathecal
IUPHAR	International Union of Pharmacologists
IV	intravenous
K _A	equilibrium dissociation constant of a drug for its receptor
K _i	inhibition constant
K _m	affinity constant of enzyme for substrate, concentration at which reaction is half of V _{max} (Michaelis-Menten dissociation constant)
LOQ	limit of quantification
LQC	low quality control
M6G	morphine-6-glucuronide
MQC	medium quality control
MS	mass spectrometry
MSC	Methadone Symptoms Checklist

MW	molecular weight
n	number within a sample
NADP(H)	nicotinamide adenine dinucleotide phosphate (reduced form)
NMR	nuclear magnetic resonance
pA ₂	measure of affinity of an antagonist to its receptor (-log K _B)
PFPA	pentafluoropropionic acid
PK	pharmacokinetic
pKa	acidity constant log ₁₀ transformed (pH at which 50% of the compound is ionised)
POMS	Profile of Mood States
QC	quality control
r	correlation coefficient
r ²	coefficient of determination
Rf	retention factor
RI	reference interval
rpm	revolutions per minute
sc	subcutaneous
SD	standard deviation
SEM	standard error of the mean
³⁵ S-GTPγS	³⁵ S-guanosine triphosphate-gamma S
SNP	single nucleotide polymorphism
t _{1/2}	half-life
tlc	thin layer chromatography
Tmax	time at which maximum concentration is achieved
UV	ultraviolet
V	rate of formation of substrate
V _d	apparent volume of distribution
V _{max}	maximum reaction velocity